Profile data is unavailable for this security.
About the company
Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.
- Revenue in USD (TTM)859.68m
- Net income in USD-1.02bn
- LocationBiohaven Pharmaceutical Holding Company Ltd215 Church StNEW HAVEN 06510-1803United StatesUSA
- Phone+1 (203) 404-0410
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|BHVN:NYQ since |
|Channel Biosciences LLC||Deal completed||25 Feb 2022||25 Feb 2022Deal completed||13.64%||1.24bn|